That’s a good hypothesis. Better sell at a discount than right off. Helps with cash flow too. Not saying that’s what happened as infringement concerns may also play a part. My bet is not a single analyst will ask this very important question but if your hypothesis is correct, we will see it on the balance sheet at least.
Kiwi, my brother and I were in business together for a long time, and "write it off" was a long standing joke with us. He was the accountant of the family and I would always say; can't we write something off. Well, I can say it is far better to dump that inventory than to write it off - especially since Amarin doesn't make money or pay taxes.
Kiwi, I did an analysis on this a few weeks ago, partially to understand cashflow. But they have been working down their inventory pretty well the past 3 years: $436,024,000 Q2 2022 415,570,000 Q3 2022 392,352,000 Q4 2022 369,543,000 Q1 2023 349,339,000 Q2 2023 346,253,000 Q3 2023 336,231,000 Q4 2023 329,505,000 Q1 2024 310,702,000 Q2 2024 298,023,000 Q3 2024 230,788,000 Q4 2024 216,894,000 Q1 2025
They will always have a fair amount of API and finished product in inventory. I'm not sure at what point their inventory is turning over pretty regularly, or what their "base" inventory value should be.
Doing a rough calculation, at 40% Cost of Goods Sold, they have around $500-550M of gross product revenue on their inventory shelves. Currently, that's about 3 years of inventory. But it's more likely around 2 years, if you consider possible growth in Europe and China and RoW. But with their required ongoing purchasing agreements, it bumps that back up a bit (to what, I don't know).
Amarin took receipt of a ton of shipments back in January and February (per the Seair website), so that contributes to this inventory number.
This working down of inventory is what has allowed them to only burn down a modest amount of cash the past few years (it has helped them conserve $150-200M of cash the past 3 years).
It would be interesting to know the exact cause behind the flip-flop with some of the insurers/PBM's. Is it pure price, or are they starting to get heat from their legal departments?
N7. Have you looked at AMRN's long term inventory ..it's in their 10Q . At some point they have to dump that on the market ...or write it off . They may have used that ( a good idea ) in a special deal , to under cut the generics for the CVS contract